FDA Approves Moderna's First mRNA Flu Vaccine for Adults 50+

What happened

The FDA approved mFlusiva, Moderna's mRNA flu vaccine, for adults aged 50 and older. The vaccine received full approval for ages 50 to 64, while adults 65 and older received accelerated approval based on immune response data. Moderna must complete an additional study to confirm benefits for the older age group. In clinical trials involving more than 40,000 adults, mFlusiva demonstrated 27% fewer confirmed flu cases compared to standard flu vaccines. The vaccine targets influenza A and B strains and showed no major safety concerns, though side effects like injection site pain, fatigue, and headache occurred slightly more often than with traditional flu shots.

Why the stock moved

The approval represents a significant commercial milestone for Moderna, as it becomes the first company to bring an mRNA flu vaccine to the U.S. market. This development follows a regulatory dispute in which the FDA initially refused to review Moderna's application due to concerns about the comparison vaccine used in trials, before reversing that decision. The approval validates Moderna's ability to apply its mRNA platform beyond COVID-19 vaccines and opens a new revenue stream in the large seasonal flu vaccine market. Limited doses are expected to reach select U.S. retailers during the fall 2026 flu season.

Bigger picture

This approval demonstrates the versatility of mRNA technology in vaccine development. Unlike traditional flu vaccines made using eggs or cells, mRNA vaccines provide instructions for the body to produce proteins that train the immune system. This approach could allow faster updates when flu strains change seasonally. For Moderna, the approval reduces reliance on COVID-19 vaccine revenue and establishes the company as a broader player in the vaccine market. The seasonal flu vaccine market serves millions of Americans annually, particularly older adults who face higher flu-related health risks.

What investors watch

Investors should monitor commercial uptake when mFlusiva launches in fall 2026, particularly pricing compared to existing flu vaccines and acceptance among healthcare providers and patients. The completion of the confirmatory study for adults 65 and older will be important for maintaining accelerated approval in that age group. Broader questions include whether Moderna can scale manufacturing efficiently and how the company positions mFlusiva against established competitors like high-dose flu shots. Long-term success will depend on whether the 27% efficacy advantage translates into market share gains and whether mRNA flu vaccines can command premium pricing.